Key facts
- YolTech Therapeutics’s last known valuation is $135.8M (Sep 2023).
- It has raised $75.1M; the latest was Early Stage VC ($45.0M) in Sep 2025.
- Notable investors include Green Pine Capital Partners, K2VC, Unity Ventures (China), Tianjin Venture Capital, Anhui Guokong Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for YolTech Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for YolTech Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About YolTech Therapeutics
Developer of in vivo gene editing therapies focusing on serious diseases using lipid nanoparticle delivery systems. The company specailises in clinical-stage therapies targeting transthyretin amyloidosis, familial hypercholesterolemia and primary hyperoxaluria type 1, thereby improving treatment outcomes through scalable, high-quality manufacturing and next-generation gene editing technologies.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- yoltx.com/
- Ownership
- Privately Held (backing)
YolTech Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in YolTech Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on YolTech Therapeutics in its N-PORT filings yet. We sweep new filings monthly.